Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“So, available evidence indicates that orforglipron achieves a safety profile that is at least comparable to injectable GLP-1 RAs while offering additional advantages related to route of administration and lack of immunogenicity [47,84,85].”
From Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes (2026) · cites this paper as [84]
In the citing paper
“Orforglipron is the first small molecule GLP-1 RA reaching phase 3 trials after demonstrating good efficacy and safety in early phase clinical trials.”
In the citing paper
“Moreover, small molecules may be easier to produce compared to peptide treatments and as a result their supply may be easier scalable to meet the constantly increasing demand for obesity pharmacotherapies [34].”
Citations
Cites
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302392 · Cited by 478
Cited by
De Giorgi, R., Ghenciulescu, A., Dziwisz, O., Taquet, M., Adler, A. I., Koychev, I., Upthegrove, R., Solmi, M., McCutcheon, R., Pillinger, T., et al. (2025) · Nature Mental Health · doi:10.1038/s44220-025-00390-x · Cited by 77
Gogineni, P., Melson, E., Papamargaritis, D., & Davies, M. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2356254 · Cited by 32
“Moreover, small molecules may be easier to produce compared to peptide treatments and as a result their supply may be easier scalable to meet the constantly increasing demand for obesity phar-macotherapies [34].”
BackgroundKansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031409 · Cited by 22
“So, available evidence indicates that orforglipron achieves a safety profile that is at least comparable to injectable GLP-1 RAs while offering additional advantages related to route of administration and lack of immunogenicity [47,84,85].”
Heckmann, N. D., Palmer, R. C., Mayfield, C. K., Gucev, G., Lieberman, J. R., & Hong, K. M. (2024) · Arthroplasty Today · doi:10.1016/j.artd.2024.101327 · Cited by 22
“Furthermore, the non-peptide structure of this medication may provide a more cost-effective alternative to the more costly peptide-based medications currently on the market [123].”
Progress Stalled? The Uncertain Future of Mortality in High‐Income Countries
Dowd, J. B., Polizzi, A., & Tilstra, A. M. (2025) · Population and Development Review · doi:10.1111/padr.12687 · Cited by 21
Metadata
- Authors
- Sidik, S.
- Corresponding author
- Sidik, Saima
- ORCID
- Sidik, Saima
- Venue
- Nature
- Published
- 2023-06-26
- Volume
- 619
- Issue
- 7968
- Pages
- 19-19
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W4382248917
- Cited by
- 18
- References
- 2
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 6 · 2023: 3
- Type
- other
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- obesity drugs, hormone mimics, weight loss, Ozempic, GLP-1 receptor agonists, drug costs, drug efficacy
- MeSH terms
- Drug Development, Semaglutide, Glucagon-Like Peptides, Fatty Acids, Humans, Obesity, Oxadiazoles, Peptides, Drug Costs, Fluorine Compounds
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective. https://app.cochat.ai/papers/10.1038/d41586-023-02092-9
- The paper
- Sidik, S. (2023). Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective. Nature. https://doi.org/10.1038/d41586-023-02092-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.